Suppr超能文献

拓扑药理学药物发现的进展:成像循环显微镜正确预测了肌萎缩侧索硬化症的一种治疗方法。

Advances in toponomics drug discovery: Imaging cycler microscopy correctly predicts a therapy method of amyotrophic lateral sclerosis.

作者信息

Schubert Walter

机构信息

Department of Medicine, Molecular Pattern Recognition Research Group, Otto Von Guericke University, Magdeburg, Germany.

出版信息

Cytometry A. 2015 Aug;87(8):696-703. doi: 10.1002/cyto.a.22671. Epub 2015 Apr 13.

Abstract

An imaging cycler microscope (ICM) is a fully automated (epi)fluorescence microscope which overcomes the spectral resolution limit resulting in parameter- and dimension-unlimited fluorescence imaging. This enables the spatial resolution of large molecular systems with their emergent topological properties (toponome) in morphologically intact cells and tissues displaying thousands of multi protein assemblies at a time. The resulting combinatorial geometry of these systems has been shown to be key for in-vivo/in-situ detection of lead proteins controlling protein network topology and (dys)function: If lead proteins are blocked or downregulated the corresponding disease protein network disassembles. Here, correct therapeutic predictions are exemplified for ALS. ICM drug target studies have discovered an 18-dimensional cell surface molecular system in ALS-PBMC with a lead drug target protein, whose therapeutic downregulation is now reported to show statistically significant effect with stop of disease progression in one third of the ALS patients. Together, this clinical and the earlier experimental validations of the ICM approach indicate that ICM readily discovers in vivo robustness nodes of disease with lead proteins controlling them. Breaking in vivo robustness nodes using drugs against their lead proteins is likely to overcome current high drug attrition rates.

摘要

成像循环显微镜(ICM)是一种全自动(落射)荧光显微镜,它克服了光谱分辨率限制,实现了参数和维度不受限的荧光成像。这使得在形态完整的细胞和组织中,能够对具有新兴拓扑特性(拓扑组)的大分子系统进行空间分辨率成像,一次显示数千个多蛋白组装体。这些系统产生的组合几何学已被证明是体内/原位检测控制蛋白质网络拓扑和(功能)异常的主导蛋白的关键:如果主导蛋白被阻断或下调,相应的疾病蛋白网络就会解体。在此,以肌萎缩侧索硬化症(ALS)为例说明了正确的治疗预测。ICM药物靶点研究在ALS患者外周血单核细胞(ALS-PBMC)中发现了一个18维的细胞表面分子系统,其主导药物靶点蛋白的治疗性下调目前据报道在三分之一的ALS患者中显示出对疾病进展停止具有统计学显著效果。总之,ICM方法的这一临床和早期实验验证表明,ICM能够轻易发现体内由主导蛋白控制的疾病稳健节点。使用针对其主导蛋白的药物打破体内稳健节点可能会克服当前高药物损耗率的问题。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/ffda/4676937/f9411b5bc3bd/cyto0087-0696-f1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验